Therapeutic human papillomavirus vaccination

Public Health Genomics

Volumn 12, Issue 5-6, 2009, Pages 331-342

  Albers, Andreas E ^a   Kaufmann, Andreas M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cervical cancer; Clinical trials, immunoevasion; Human papillomavirus; Immunomodulation; Immunotherapy; Squamous cell carcinoma, head and neck; Therapeutic vaccine

Indexed keywords

VIRUS ANTIGEN; WART VIRUS VACCINE;

CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG SAFETY; EPITHELIUM TUMOR; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR CELL; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS ONCOGENE; WART VIRUS;

ANTIGEN-PRESENTING CELLS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MALE; MODELS, BIOLOGICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 69249158173     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214923     Document Type: Review

References (85)

1. Munoz N, Bosch FX, de Sanjose S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
3. Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
4. Herrero R, Castellsague X, Pawlita M, et al: Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-1783.
5. Koutsky L: Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 3-8.
6. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, Abrahamsen M, Inserra P, Olvera S, Hatch K: Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002; 15: 462-469.
7. Moscicki AB: Conservative management of adolescents with abnormal cytology and histology. J Natl Compr Canc Netw 2008; 6: 101-106.
8. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079.
9. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B: Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001; 19: 1211-1220.
10. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M: Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998; 352: 1441-1442.
11. Zehbe I, Wilander E, Delius H, Tommasino M: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 1998; 58: 829-833.
12. Berumen J, Ordoñez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal- de la Campa A: Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst 2001; 93: 1325-1330.
13. Lee K, Magalhaes I, Clavel C, Briolat J, Birembaut P, Tommasino M, Zehbe I: Human papillomavirus 16 E6, L1, L2 and E2 gene variants in cervical lesion progression. Virus Res 2008; 131: 106-110.
14. Seedorf K, Krämmer G, Dürst M, Suhai S, Röwekamp WG: Human papillomavirus type 16 DNA sequence. Virology 1985; 145: 181-185.
15. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM: Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997; 71: 2463-2472.
16. Lambropoulos AF, Agorastos T, Foka ZJ, Chrisafi S, Constantinidis TC, Bontis J, Kotsis A: Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett 2003; 191: 187-191.
17. Zoodsma M, Nolte IM, Te Meerman GJ, De Vries EG, Van der Zee AG: HLA genes and other candidate genes involved in susceptibility for (pre)neoplastic cervical disease. Int J Oncol 2005; 26: 769-784.
18. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E: Obsetric outcomes after conservative treatments for intraepithelial or early invasive cervical lesions. Lancet 2006; 367: 489-498.
19. Parkin DM: The global health burden of infection- associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-3044.
20. Future II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
21. Harper DM, Franco EL, Wheeler CM, et al: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: followup from a randomised control trial. Lancet 2006; 367: 1247-1255.
22. Paavonen J, Jenkins D, Bosch FX, et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.
23. Hildesheim A, Herrero R, Wacholder S, et al: Effect of human papillomavirus 16/18 L1 virus- like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743-753.
24. Fakhry C, D'Souza G, Sugar E, et al: Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 2006; 44: 4479-4485.
25. Mashberg A: Head and neck cancer. N Engl J Med 1993; 328: 1783; author reply 1784.
26. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 1993; 328: 184-194.
27. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
28. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
29. Jones AS, Morar P, Phillips DE, et al: Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995; 75: 1343-1353.
30. Leemans CR, Tiwari R, Nauta JJ, et al: Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994; 73: 187-190.
31. Argiris A, Eng C: Epidemiology, staging, and screening of head and neck cancer. Cancer Treat Res 2003; 114: 15-60.
32. Kreimer AR, Clifford GM, Boyle P, et al: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475.
33. Syrjanen S: Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005; 32(suppl 1):S59-S66.
34. Gillison ML, Shah KV: Human papillomavirus- associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 2001; 13: 183-188.
35. Gillison ML, Lowy DR: A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363: 1488-1489.
36. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
37. Smith EM, Summersgill KF, Allen J, et al: Human papillomavirus and risk of laryngeal cancer. Ann Otol Rhinol Laryngol 2000; 109: 1069-1076.
38. Hobbs CG, Sterne JA, Bailey M, et al: Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31: 259-266.
39. Mork J, Lie AK, Glattre E, et al: Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-1131.
40. Schwartz SM, Daling JR, Doody DR, et al: Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 1626-1636.
41. Zumbach K, Kisseljov F, Sacharova O, et al: Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer 2000; 85: 313-318.
42. Smith EM, Ritchie JM, Summersgill KF, et al: Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 108: 766-772.
43. Kreimer AR, Alberg AJ, Daniel R, et al: Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 2004; 189: 686-698.
44. Gillison ML, Koch WM, Shah KV: Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Curr Opin Oncol 1999; 11: 191-199.
45. Fakhry C, Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24: 2606-2611.
46. Cruz IB, Snijders PJ, Steenbergen RD, et al: Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 1996; 32B:55-62.
47. Smith EM, Ritchie JM, Summersgill KF, et al: Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96: 449-455.
48. Licitra L, Perrone F, Bossi P, et al: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-5636.
49. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
50. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus- positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
51. Ritchie JM, Smith EM, Summersgill KF, et al: Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 336-344.
52. Hafkamp HC, Manni JJ, Speel EJ: Role of human papillomavirus in the development of head and neck squamous cell carcinomas. Acta Otolaryngol 2004; 124: 520-526.
53. Pintos J, Franco EL, Black MJ, et al: Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 1999; 85: 1903-1909.
54. Albers A, Abe K, Hunt J, et al: Antitumor activity of human papillomavirus type 16 E7- specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005; 65: 11146-11155.
55. Hoffmann TK, Arsov C, Schirlau K, et al: T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 2006; 118: 1984-1991.
56. Brinkman JA, Hughes SH, Stone P, et al: Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007; 23: 337-352.
57. de Jong A, van der Burg SH, Kwappenberg KM, et al: Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 472-479.
58. Welters MJ, de Jong A, van den Eeden SJ, et al: Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003; 63: 636-641.
59. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al: Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006; 13: 592-597.
60. Molling JW, de Gruijl TD, Glim J, et al: CD4(+)CD25(hi) regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007; 121: 1749-1755.
61. Stanley MA: Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-577.
62. Schreckenberger C, Kaufmann AM: Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004; 16: 485-491.
63. Muderspach L, Wilczynski S, Roman L, et al: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with highgrade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6: 3406-3416.
64. Roman LD, Wilczynski S, Muderspach LI, et al: A phase II study of Hsp-E7 (SGN-00101) in women with high grade cervical dysplasia. Gynecol Oncol 2007; 106: 558-566.
65. Einstein MH, Kadish AS, Burk RD, et al: Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007; 106: 453-460.
66. Palefsky JM, Berry JM, Jay N, et al: A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 2006; 20: 1151-1155.
67. Derkay CS, Smith RJ, McClay J, et al: HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 2005; 114: 730-737.
68. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ: Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008; 14: 169-177.
69. Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH: Induction of tumorspecific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008; 14: 178-187.
70. Müller M, Zhou J, Reed TD, et al: Chimeric papillomavirus-like particles. Virology 1997; 234: 93-111.
71. Schäfer K, Müller M, Faath S, et al: Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999; 81: 881-888.
72. Kaufmann AM, Nieland J, Schinz M, et al: HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001; 92: 285-293.
73. Kaufmann AM, Nieland JD, Jochmus I, et al: Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007; 121: 2794-2800.
74. Kaufmann AM, Stern PL, Rankin EM, et al: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002; 8: 3676-3685.
75. Fiander AN, Tristram AJ, Davidson EJ, et al: Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006; 16: 1075-1081.
76. Nonn M, Schinz M, Zumbach K, et al: Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. J Cancer Res Clin Oncol 2003; 129: 511-520.
77. Ferrara A, Nonn M, Sehr P, et al: Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003; 129: 521-530.
78. Santin AD, Bellone S, Palmieri M, et al: Human papillomavirus type 16 and 18 E7- pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating- dose trial. J Virol 2008; 82: 1968-1979.
79. Bergmann C, Strauss L, Wieckowski E, Czystowska M, Albers A, Wang Y, Zeidler R, Lang S, Whiteside TL: Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 2008; 31: 371-380.
80. Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL: Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005; 54: 1072-1081.
81. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL: Characteristics of CD4+ CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92: 913-920.
82. Rosenberg SA, Yang JC, Sherry RM, et al: Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanomamelanocyte antigen. Hum Gene Ther 2003; 14: 709-714.
83. Miller AM, Ozenci V, Kiessling R, Pisa P: Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormonerefractory prostate cancer. J Immunother 2005; 28: 389-395.
84. Ohlschlager P, Pes M, Osen W, et al: An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006; 24: 2880-2893.
85. Lu Y, Zhang Z, Liu Q, et al: Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein basedvaccine in a Hu-PBL-SCID mouse model. Biol Pharm Bull 2007; 30: 150-156.